Conatus Raises $20 Million for Hepatitis C Studies

San Diego’s Conatus Pharmaceuticals, which specializes in developing drugs for liver disease and cancers, said it closed on a $20 million block of equity funding, which was led by a new investor, AgeChem Venture Fund of Montreal.
Xconomy